Â鶹´«Ã½¸ßÇå

Dr. Abraham focuses on vision loss and its impact on aging outcomes with current work in community vision screening for aging adults, particularly those aging with HIV.

Jeffrey Bennett, MD, PhD 
The Bennett laboratory is interested in understanding the pathogenesis of inflammatory disorders of the central nervous system and optic nerve: multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody-associated disorder.

The Brzezinski Lab studies the genetic mechanisms that control mouse and human retinal development.

Brian Bucca, OD

Dr. Chauhan's research focuses on developing novel formulations and devices for delivering ophthalmic drugs and mechanistic pharmacokinetic models.

Development of novel 3D retinal tissues derived from human induced pluripotent stem cells and their use as platforms for developing new treatments for blinding diseases.

The Denman laboratory studies how neurons and neural interactions - within neocortical visual areas and distributed across the brain- generate successful visual perceptions using quantitative psychophysics, in vivo high-density electrophysiology, in vivo imaging, circuit tracing, and computational methods. 

The long-term goal of the research carried out by Dr. Flores-Bellver's team is to contribute to a better understanding of the early events involved in early Age-related Macular Degeneration (AMD), including drusen biogenesis.

The Hassman Lab aims to identify therapeutic targets for uveitis, or ocular inflammatory disease, by combining genomic analysis of patients with in vitro and in vivo models to dissect pathophysiologic mechanisms.

The Division of Artificial Intelligence in Ophthalmology focuses on developing, evaluating, and deploying AI solutions in healthcare with a focus on ophthalmology.

Jason Kolfenbach, MD

The Kompella laboratory focuses on drug and gene delivery research, with a focus on formulations, nanomedicines, and pharmacokinetics.

Our group is interested in the development of cell-interactive biopolymer systems that will allow the study of cells’ interactions with their microenvironment. These systems can be used for tissue regeneration and the discovery of therapeutics, including for glaucoma.

Daniel Labarbera, PhD

The goal of the Li Lab's research is to develop, evaluate, and disseminate methods for comparing healthcare interventions and to provide trustworthy evidence for decision making. She directs the NEI-funded Cochrane Eyes and Vision US Project.

Dr. Liu is interested in leveraging electronic health record data to inform clinical practice and policies with a specific focus on dry eye. 

Dr. Lynch investigates the role of systemic inflammatory biomarkers in age-related macular degeneration along with the links between maternal complications of pregnancy and the development of retinopathy of prematurity.

Dr. Nagaraj's laboratory investigates mechanisms and develops therapeutic interventions for secondary cataracts, and neurovascular degeneration in glaucoma and diabetes.

Dr. Nam's research primarily focuses on developing neuroprotective therapeutics for retinal ganglion cells (RCGs) in animal models of eye diseases, with a particular emphasis on glaucoma and traumatic optic neuropathies.

 
Dr. Patnaik focuses on age-related macular degeneration, retinopathy of prematurity, cataract and glaucoma surgeries, and other ophthalmic diseases. She is especially interested in assessing disparities in ocular disease.

 
Dr. Pelak’s research focuses on the processing of vision in the brain in association with aging and with neurodegenerative diseases such as Alzheimer’s disease.

 
Dr. Petrash is a retired professor who continues to collaborate to study cataract mechanisms and novel therapies to reverse lens opacification and prevent the post-surgical development of capsule opacification.

Alon Poleg-Polsky, MD, PhD
Dr. Poleg-Polsky uses electrophysiology, 2-photon imaging, and machine learning to understand visual computations in the rodent retina.

Dr. Qureshi is interested in the methods used to investigate the harms of interventions at different levels of evidence, from adverse events collected and reported in clinical trials to the synthesis of harms in systematic reviews.

 
The Vergara Lab uses stem cell technologies to model developmental abnormalities and degenerative diseases of the human retina, with the goal of advancing novel treatments to prevent vision loss or blindness.

 
Dr. Washington's research interests include a comprehensive approach to research in whole eye transplantation and improving peripheral and central nerve regeneration after injury and in the setting of vascularized composite allotransplantation.